Cargando…
Anti-tumour effect of tocilizumab for osteosarcoma cell lines
AIMS: Tocilizumab, an interleukin-6 (IL-6) receptor (IL-6R) targeting antibody, enhances the anti-tumour effect of conventional chemotherapy in preclinical models of cancer. We investigated the anti-tumour effect of tocilizumab in osteosarcoma (OS) cell lines. METHODS: We used the 143B, HOS, and Sao...
Autores principales: | Hagi, Tomohito, Nakamura, Tomoki, Kita, Kouji, Iino, Takahiro, Asanuma, Kunihiro, Sudo, Akihiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Editorial Society of Bone & Joint Surgery
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672325/ https://www.ncbi.nlm.nih.gov/pubmed/33179539 http://dx.doi.org/10.1302/2046-3758.911.BJR-2020-0123.R1 |
Ejemplares similares
-
Radiodynamic therapy with acridine orange local administration as a new treatment option for primary and secondary bone tumours
por: Matsuyama, Yumi, et al.
Publicado: (2022) -
Expression of Interleukin-6 and the Interleukin-6 Receptor Predicts the Clinical Outcomes of Patients with Soft Tissue Sarcomas
por: Nakamura, Koichi, et al.
Publicado: (2020) -
Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas
por: Asanuma, Kunihiro, et al.
Publicado: (2020) -
Macrophages and vimentin in tissues adjacent to megaprostheses and mesh in reconstructive surgeries
por: Asanuma, Kunihiro, et al.
Publicado: (2022) -
Full-thickness chest wall resection for malignant chest wall tumors and postoperative problems
por: Asanuma, Kunihiro, et al.
Publicado: (2023)